Reduced levels of 5‐α reductase 2 in adult prostate tissue and implications for BPH therapy

5‐α reductase 2 (5‐AR 2) is a key enzyme that is responsible of proper development of prostate tissue. Inhibition of 5‐AR 2 has proven to be efficacious for management of urinary symptoms secondary benign prostatic hyperplasia (BPH). However, some patients are resistant to the therapeutic effects of 5‐AR 2 inhibitor. We wished to determine why some benign non‐cancerous adult human prostates do not express 5‐AR 2, and hypothesized that methylation of 5‐AR 2 promoter region correlated with low expression of 5‐AR 2 protein.

[1]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[2]  M. Fraga,et al.  The role of epigenetics in aging and age-related diseases , 2009, Ageing Research Reviews.

[3]  C. Roehrborn,et al.  Pathology of benign prostatic hyperplasia , 2008, International Journal of Impotence Research.

[4]  I. Thompson,et al.  Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach , 2008, Cancer Prevention Research.

[5]  I. Thompson,et al.  Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention , 2008, Cancer Prevention Research.

[6]  L. Groop,et al.  Age influences DNA methylation and gene expression of COX7A1 in human skeletal muscle , 2008, Diabetologia.

[7]  D. Tindall,et al.  Type 1 and Type 2 5α-Reductase Expression in the Development and Progression of Prostate Cancer , 2008 .

[8]  P. Febbo,et al.  Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. , 2007, The American journal of pathology.

[9]  M. Kattan,et al.  Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.

[10]  I. Thompson,et al.  Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. , 2007, Journal of Clinical Oncology.

[11]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[12]  I. Thompson,et al.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. , 2006, Journal of the National Cancer Institute.

[13]  T. Bullock,et al.  Emerging drug therapies for benign prostatic hyperplasia , 2006, Expert opinion on emerging drugs.

[14]  D. Peehl,et al.  Expression of transforming growth factor‐beta 1 and growth in soft agar differentiate prostate carcinoma‐associated fibroblasts from normal prostate fibroblasts , 2004, International journal of cancer.

[15]  Hongmei Yang,et al.  Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand–Mediated Apoptosis in Prostate Cancer , 2004, Cancer Research.

[16]  J. Issa,et al.  Age-related epigenetic changes and the immune system. , 2003, Clinical immunology.

[17]  I. Thompson,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[18]  J. Waldstreicher,et al.  Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. , 1999, Urology.

[19]  Ximing J. Yang,et al.  Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? , 1999 .

[20]  S. Baylin,et al.  Aging and DNA methylation in colorectal mucosa and cancer. , 1998, Cancer research.

[21]  E. Crawford,et al.  Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. , 1998, Urology.

[22]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. , 1998, The New England journal of medicine.

[23]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia , 1998 .

[24]  N. Bruchovsky,et al.  Characterization of 5α-reductase gene expression in stroma and epithelium of human prostate , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  S. Baylin,et al.  Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Labrecque,et al.  Viability of wild type p53-containing and p53-deficient tumor cells following anticancer treatment: the use of human papillomavirus E6 to target p53. , 1995, Oncogene.

[27]  G. Cunha.  Role of mesenchymal‐epithelial interactions in normal and abnormal development of the mammary gland and prostate , 1994, Cancer.

[28]  M. Becich,et al.  The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. , 1992, The Journal of urology.

[29]  Ellen Shapiro,et al.  Quantifying the Smooth Muscle Content of the Prostate Using Double Immunoenzymatic Staining and Color-Assisted Image Analysis , 1992 .

[30]  R. Babaian,et al.  The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. , 1992, The Journal of urology.

[31]  S. J. Higgins,et al.  The endocrinology and developmental biology of the prostate. , 1987, Endocrine reviews.

[32]  R. E. Peterson,et al.  Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. , 1975, Science.

[33]  R. E. Peterson,et al.  Steroid 5α-Reductase Deficiency in Man: An Inherited Form of Male Pseudohermaphroditism , 1974, Science.

[34]  J. D. Wilson,et al.  Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. , 1974, The New England journal of medicine.

[35]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[36]  D. Tindall,et al.  Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. , 2008, European urology.

[37]  P. Schellhammer,et al.  Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. , 1999, Urology.

[38]  P. Walsh.  Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. , 1999, The Journal of urology.

[39]  S. Baylin,et al.  Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon , 1994, Nature Genetics.

[40]  J. McNeal.  Origin and evolution of benign prostatic enlargement. , 1978, Investigative urology.